Hims & Hers Launches Unapproved Compounded Peptide Treatments
The telehealth company adds five FDA-unapproved compounds to its menu following regulatory shifts that have expanded the market for such treatments.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
First reported by CNBC, 5h 04m ahead of the next publisher · who breaks stories first
This story has stopped developing; this page is its permanent record. More from that day
The odds
Each tick is a source publishing on this story · 1 more published before price tracking began
Price data
| Time | Chance of yes |
|---|---|
| now | 75% |
| 18 Nov, 16:19 UTC | 75% |
The story so far
3 publishers have covered this in 4 articles since 18 Nov 2026. CNBC published first, on 18 November at 14:02 UTC; Quartz followed 5h 04m later. The most recent article, from STAT, appeared on 19 November at 16:59 UTC.
Outlets reporting it: CNBC (major outlet), Quartz, STAT.
One prediction market prices this story:
- BPC-157 — the market puts it at 75%, closing 1 Oct 2027. The outcome is Yes if the FDA publishes a proposed rule adding BPC-157 or its acetate form to the 503A Bulks List before October 1, 2027. Otherwise, the outcome is No. Readers often mistake the launch of compounded treatments for an official FDA action.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
How it unfolded
Every source in the order it published, with the odds on BPC-157 at that moment. A dash means the source published before we started tracking prices.
- CNBCHims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy—
- QuartzHims & Hers is launching five compounded peptide treatments not approved by the FDA75%
- QuartzHims & Hers bringt fünf zusammengesetzte Peptidbehandlungen auf den Markt, die nicht von der FDA zugelassen sind.75%
- STATSTAT+: Peptide market poised to explode with new Hims and Noom launches75%
- Current odds75%
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy CNBC ·
- STAT+: Peptide market poised to explode with new Hims and Noom launches STAT
- Hims & Hers bringt fünf zusammengesetzte Peptidbehandlungen auf den Markt, die nicht von der FDA zugelassen sind. Quartz
- Hims & Hers is launching five compounded peptide treatments not approved by the FDA Quartz
Related prediction markets
Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right
- Kalshi BPC-157 · Which peptides will the FDA propose adding to the 503A Bulks List? 75%
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Alert me when the odds move
In this story
- Hims & Hers
- Noom
- FDA
- HHS